Mecamylamine

CHEMBL267936 Phase 4 승인됨 Small molecule
Half-Life
Bioavailability
Protein Binding
Molecular Weight
167.3 g/mol
LogP
2.6
Phase
4

A ganglionic blocker that lowers blood pressure by blocking nerve signals that constrict blood vessels, used to treat severe hypertension and also studied for nicotine addiction. It reduces sympathetic nervous system activity to cause vasodilation.

분자량

167.2900 g/mol

LogP

2.60

TPSA

12.00 Ų

리핀스키 5의 법칙

통과

치료 영역

Pharmacokinetics (PK)

Pharmacodynamics (PD)

2D 구조

SVG PNG

Cite this structure


                        

Embed this structure


                        

SMILES

CNC1(C)C2CCC(C2)C1(C)C

InChI

InChI=1S/C11H21N/c1-10(2)8-5-6-9(7-8)11(10,3)12-4/h8-9,12H,5-7H2,1-4H3

Molecular Formula

C11H21N

HBD / HBA

1 / 1

회전 가능 결합

1

무거운 원자

12

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

자주 묻는 질문

A ganglionic blocker that lowers blood pressure by blocking nerve signals that constrict blood vessels, used to treat severe hypertension and also studied for nicotine addiction. It reduces sympathetic nervous system activity to cause vasodilation.

Yes, Mecamylamine is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

  • ChEMBL — European Bioinformatics Institute (EBI). CHEMBL267936. Open-access bioactivity database.
  • PubChem — National Center for Biotechnology Information (NCBI). CID 4032. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.

의학적 면책조항

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.